甲基化受体-1-介导肠道炎症作为炎症性肠病的治疗点
Milly J McAllister1, Rebecca Hall1, Robert J Whelan1
1Edinburgh IBD Science Unit, Centre for Inflammation Research, Queens Medical Research Unit, University of Edinburgh, Edinburgh, Scotland, UK.
Crohn's & colitis 360
|February 14, 2024
概括
甲基化受体 (FPR) -1 在炎症性肠病 (IBD) 中驱动炎症. 阻断FPR1显示了治疗潜力,但线粒体需要进一步研究作为生物标志物.
科学领域:
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
- 分子生物学分子生物学
背景情况:
- 甲基化受体 (FPR) -1 是一种与G蛋白结合的受体,对于感知甲基化 (FP) 和激活天生的免疫力至关重要.
- FPR1在感知外来细菌和宿主衍生的线粒体FP方面发挥着作用.
研究的目的:
- 研究FPR1-介导炎症在炎症性肠病 (IBD) 中的作用.
- 探索FPR1作为IBD的潜在治疗点.
- 评估线粒体FP作为IBD的潜在生物标志物.
主要方法:
- 在人类IBD数据集中分析FPR1基因和蛋白质表达.
- 在体内研究使用 FPR1 在硫酸 (DSS) 大肠炎模型中淘汰小鼠.
- 使用线粒体FP和FPR1阻塞用环素H对人类中性粒细胞的ex vivo研究.
- 在IBD患者的血液和便样本中查线粒体ND6.
主要成果:
- 在IBD患者中,FPR1的表达很高,并且与性结肠炎 (UC) 和克罗恩病 (CD) 中的肠道炎症相关.
- 在炎症IBD肠道组织中,FPR1+ve中性粒细胞显著增加.
- 在小鼠中,FPR1基因删除可以保护小鼠免受DSS结肠炎的侵害.
- 线粒体FP,ND6,激活人类中性粒细胞,这种作用被环素H抑制.
- 在IBD患者的便中检测到ND6,但与疾病活动标志物无关.
结论:
- 以FPR1为媒介的中性友炎症是IBD的潜在治疗点.
- 需要进一步的研究来确定线粒体FP作为患者分层的生物标志物的临床实用性.
关键词:
污水堆 (DAMP) 是一种污水堆.一个叫FPR的F1IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD线粒体中的线粒体.中性粒细胞中性粒细胞.更多相关视频
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
334
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
164
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
164
Drugs for Treatment of Ulcerative Colitis in IBD
141
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
141
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
119
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
119


